
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 2)*

Kezar Life Sciences, Inc.

(Name of Issuer)

Common Stock, par value \$0.001 per share

(Title of Class of Securities)

(CUSIP Number)

Kevin Tang
4747 Executive Drive, Suite 210
San Diego, CA, 92121
858-200-3830

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

05/11/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No.

Name of reporting person

1 TANG CAPITAL MANAGEMENT, LLC

2 Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

3 SEC use only
Source of funds (See Instructions)

4 WC
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5
Citizenship or place of organization

6 DELAWARE

Sole Voting Power

7

0.00

Number of
Shares

Shared Voting Power

Beneficially 8

0.00

Owned by

Sole Dispositive Power

Each

9

0.00

Reporting

Shared Dispositive Power

Person

With:

10

0.00

Aggregate amount beneficially owned by each reporting person

11 0.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12
Percent of class represented by amount in Row (11)

13 0 %

Type of Reporting Person (See Instructions)

14 OO

SCHEDULE 13D

CUSIP No.

Name of reporting person

1 KEVIN TANG

Check the appropriate box if a member of a Group (See Instructions)

2 (a)
 (b)

3 SEC use only
Source of funds (See Instructions)

4 WC
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5
Citizenship or place of organization

6 UNITED STATES

Number of 7 Sole Voting Power

Shares Beneficially Owned by Each Reporting Person With: 0.00
 Shared Voting Power
 8
 0.00
 Sole Dispositive Power
 9
 0.00
 Shared Dispositive Power
 10
 0.00
 Aggregate amount beneficially owned by each reporting person
 11
 0.00
 Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
 12

 Percent of class represented by amount in Row (11)
 13
 0 %
 Type of Reporting Person (See Instructions)
 14
 IN

SCHEDULE 13D

CUSIP No.

1 Name of reporting person
 TANG CAPITAL PARTNERS, LP
 Check the appropriate box if a member of a Group (See Instructions)
 2
 (a)
 (b)
 3 SEC use only
 Source of funds (See Instructions)
 4
 WC
 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
 5

 Citizenship or place of organization
 6
 DELAWARE
 Sole Voting Power
 7
 0.00
 Number of Shares Beneficially Owned by Each Reporting Person With: 8
 Shared Voting Power
 0.00
 Sole Dispositive Power
 9
 0.00
 Shared Dispositive Power
 10
 0.00
 11 Aggregate amount beneficially owned by each reporting person

12 0.00
 Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13 Percent of class represented by amount in Row (11)
 0 %

14 Type of Reporting Person (See Instructions)
 PN

SCHEDULE 13D

CUSIP No.

1 Name of reporting person
 TANG CAPITAL PARTNERS INTERNATIONAL, LP
 Check the appropriate box if a member of a Group (See Instructions)

2 (a)
 (b)

3 SEC use only

4 Source of funds (See Instructions)
 WC

5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6 Citizenship or place of organization
 DELAWARE

7 Sole Voting Power
 0.00

Number of Shares Beneficially Owned by Each Reporting Person With: 8 Shared Voting Power
 0.00

9 Sole Dispositive Power
 0.00

10 Shared Dispositive Power
 0.00

11 Aggregate amount beneficially owned by each reporting person
 0.00

12 Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13 Percent of class represented by amount in Row (11)
 0 %

14 Type of Reporting Person (See Instructions)
 PN

SCHEDULE 13D

CUSIP No.

1 Name of reporting person
TANG CAPITAL PARTNERS III, INC
Check the appropriate box if a member of a Group (See Instructions)

2 (a)
 (b)

3 SEC use only

4 Source of funds (See Instructions)

5 WC
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6
Citizenship or place of organization
NEVADA

7 Sole Voting Power
0.00

Number of Shares Beneficially Owned by Each Reporting Person With:

8 Shared Voting Power
0.00

9 Sole Dispositive Power
0.00

10 Shared Dispositive Power
0.00

11 Aggregate amount beneficially owned by each reporting person
0.00

12 Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13
Percent of class represented by amount in Row (11)
0 %

14 Type of Reporting Person (See Instructions)
CO

SCHEDULE 13D

CUSIP No.

1 Name of reporting person
TANG CAPITAL PARTNERS IV, INC
Check the appropriate box if a member of a Group (See Instructions)

2 (a)
 (b)

3 SEC use only
Source of funds (See Instructions)

4 WC
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5
Citizenship or place of organization

6 NEVADA

7 Sole Voting Power

Number of Shares Beneficially Owned by Each Reporting Person With: 8 0.00
Shared Voting Power

9 0.00
Sole Dispositive Power

10 0.00
Shared Dispositive Power

11 Aggregate amount beneficially owned by each reporting person

12 0.00
Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13
Percent of class represented by amount in Row (11)

14 0 %
Type of Reporting Person (See Instructions)

CO

SCHEDULE 13D

CUSIP No.

1 Name of reporting person
CONCENTRA BIOSCIENCES, LLC
Check the appropriate box if a member of a Group (See Instructions)

2 (a)
 (b)

3 SEC use only
Source of funds (See Instructions)

4 WC
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5
Citizenship or place of organization

6 DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With: 7 Sole Voting Power

8 0.00

Owned by 8 Shared Voting Power
Each
Reporting 0.00
Person Sole Dispositive Power
With: 9
0.00
Shared Dispositive Power
10
0.00

Aggregate amount beneficially owned by each reporting person

11
0.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12

Percent of class represented by amount in Row (11)

13
0 %

Type of Reporting Person (See Instructions)

14
OO

SCHEDULE 13D

Item 1. Security and Issuer

Title of Class of Securities:

(a) Common Stock, par value \$0.001 per share

Name of Issuer:

(b) Kezar Life Sciences, Inc.

Address of Issuer's Principal Executive Offices:

(c) 4000 Shoreline Court, Suite 300, South San Francisco, CALIFORNIA , 94080.

Item 1 This Schedule 13D/A (this "Statement") amends the Schedule 13D (the "Original Schedule 13D") filed on October 8, 2024 as amended on April 1, 2026. Items 4 and 5 of the Statement are hereby amended and supplemented to the extent hereinafter expressly set forth. Except as amended hereby, the original disclosure set forth in the Statement shall remain unchanged. All capitalized terms used and not expressly defined herein have the respective meanings ascribed to such terms in the Original Schedule 13D.

Item 4. Purpose of Transaction

Item 4 of the Original Schedule 13D is hereby amended to add the following: Closing of the Merger: On May 11, 2026, the Issuer completed its merger with Aurinia Pharma U.S., Inc. ("Parent") and Parent's wholly-owned subsidiary, Aurinia Merger Sub, Inc. ("Merger Sub") pursuant to the terms of the Merger Agreement, whereby Merger Sub merged with and into the Issuer, in accordance with the General Corporation Law of the State of Delaware, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the Merger Agreement, on May 11, 2026, each issued and outstanding share of the Issuer's Common Stock was cancelled.

Item 5. Interest in Securities of the Issuer

The information previously provided in response to Item 5 is hereby amended and restated by replacing the text thereof in its entirety with the following: The information set forth in the cover pages of this Schedule 13D is hereby incorporated by reference into this Item 5. As of the date hereof the Reporting Persons do not own any shares of the Issuer's Common Stock.

(a) See item 5(a) above.

(b) Except as described in this Amendment No. 2, there have been no transactions in the Issuer's Common Stock during the past 60 days by the Reporting Persons.

(c) No person other than a Reporting Person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, Common Stock beneficially owned by the Reporting Persons.

(d) The Reporting Persons ceased to be beneficial owners of 5% or more of the Issuer's Common Stock on May 11, 2026.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

TANG CAPITAL MANAGEMENT, LLC

Signature: /s/ Kevin Tang
Name/Title: Manager
Date: 05/13/2026

KEVIN TANG

Signature: /s/ Kevin Tang
Name/Title: Self
Date: 05/13/2026

TANG CAPITAL PARTNERS, LP

Signature: /s/ Kevin Tang
Name/Title: Manager, Tang Capital Management, LLC,
General Partner
Date: 05/13/2026

TANG CAPITAL PARTNERS INTERNATIONAL, LP

Signature: /s/ Kevin Tang
Name/Title: Manager, Tang Capital Management, LLC,
General Partner
Date: 05/13/2026

TANG CAPITAL PARTNERS III, INC

Signature: /s/ Kevin Tang
Name/Title: Chief Executive Officer
Date: 05/13/2026

TANG CAPITAL PARTNERS IV, INC

Signature: /s/ Kevin Tang
Name/Title: Chief Executive Officer
Date: 05/13/2026

CONCENTRA BIOSCIENCES, LLC

Signature: /s/ Kevin Tang
Name/Title: Chief Executive Officer
Date: 05/13/2026